Google Tests Catching Heart, Eye Issues From Smartphone Sensors
Google announced on Thursday its latest plans for using smartphones to monitor health, saying it would test whether capturing heart sounds and eyeball images could help people identify issues from home. The company, a unit of Alphabet Inc, is investigating whether the...
Pfizer Notches Breakthrough Status in Race to an RSV Vaccine
Pfizer has announced Thursday that it received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its vaccine candidate PF-06928316 (RSVpreF), intended to prevent infections caused by a respiratory syncytial virus (RSV). The respiratory...
With Robust Results, Moderna to Request Vaccine EUA for Kids Under 6
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age. The data showed a “robust neutralizing antibody response” in both cohorts. The doses were...
Takeda’s Parathyroid Hormone Injection Delayed Indefinitely
Takeda faces yet another setback by the U.S. Food and Drug Administration for its parathyroid hormone, natpara. Natpara is intended to help patients navigate low blood calcium due to hypoparathyroidism. In Sept. 2019, Takeda issued a U.S. recall of all natpara for...
A New Day in Cancer Treatment: FDA Approves BMS’s Opdualag
Bristol Myers Squibb (BMS) achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of patients 12 and older with unresctable or metastatic melanoma. The decision is based on the...
Moderna and Pfizer are seeking FDA approval for second COVID-19 boosters.
Moderna formally requested the FDA grant emergency authorization for a second booster shot of its COVID-19 vaccine for all adults over 18 who have received approved vaccines. Earlier this week, Pfizer and its partner BioNTech also requested authorization for a second...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com